Every Form 4 that Elevance Health Inc (ELV) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ELV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ELV filings page.
Elevance Health, Inc. executive Erin M. Wessling, EVP & Chief Legal Officer, reported two transactions in Elevance Health common stock. On September 3, 2026, 255 shares were disposed of at $414.78 per share, and on September 2, 2026, 94 shares were disposed of at $405.84 per share. Both transactions are identified as payment of tax liability by withholding stock incident to the vesting of previously granted restricted stock, and no Rule 10b5-1 trading plan is reported.
Elevance Health, Inc. (ELV) reported that EVP & Chief HR Officer Ryan R. Craig had 144 shares of common stock withheld on September 2, 2026 to pay tax liability associated with the vesting of previously granted restricted stock. The shares were valued at $405.84 per share, and Craig now holds 6,530 shares directly. No Rule 10b5-1 trading plan is reported for this transaction.
Elevance Health director Ramiro G Peru purchased 1,000 shares of common stock on 2026-07-17 at $366.05 per share. Following this open-market transaction, he directly owns 10,908 shares of Elevance Health, Inc. common stock.
Elevance Health, Inc. President and CEO Gail Boudreaux reported purchases of a total of 2,725 shares of common stock on July 17, 2026. She bought 680 shares at a weighted-average price of $366.41 (with trade prices from $366.14 to $366.48) and 2,045 shares at a weighted-average price of $368.25 (with trade prices from $367.76 to $368.69). After these transactions, she directly holds 171,976 shares and indirectly holds 60 shares through her spouse’s revocable trust. The Rule 10b5-1 trading plan checkbox was not marked for these transactions.
Elevance Health, Inc. Chief Accounting Officer and Controller Ronald W. Penczek reported an open-market sale of 369 shares of common stock. The weighted average sale price was $403.16 per share, with individual trades priced between $403.15 and $403.31. Following this transaction, he directly owns 3,740 shares.
Elevance Health, Inc. director Robert L. Dixon Jr. reported an open-market sale of company stock. He sold 151 shares of common stock at a price of $401.77 per share on June 11, 2026. After this transaction, he directly holds 10,734 shares of Elevance Health common stock.
Elevance Health, Inc. chief accounting officer and controller Ronald W. Penczek exercised employee stock options for a total of 1,531 shares of common stock and sold 1,531 shares in an open-market transaction at $403.13 per share. Following these transactions, he directly holds 4,109 shares of Elevance Health common stock. The balance includes 10.21 shares acquired earlier through a dividend reinvestment plan.
STRABLE-SOETHOUT DEANNA D reported acquisition or exercise transactions in this Form 4 filing.
Elevance Health, Inc. director Deanna D. Strable-Soethout received a grant of 563 deferred stock units of common stock as part of the company’s Board of Directors Compensation Program. The award was at no cash cost per unit and brings her reported deferred stock unit holdings to 2,209.
The deferred stock units will be settled in Elevance Health common stock upon the earlier of five years from the grant date or when she ceases to be a board member, unless she has elected a later payout date under the Board of Directors Deferred Compensation Plan.
SCHULMAN AMY W reported acquisition or exercise transactions in this Form 4 filing.
Elevance Health director Amy W. Schulman received an equity award of 563 deferred stock units of common stock under the company’s Board of Directors Compensation Program. This grant increased her directly held equity-related position to 781 shares-equivalent, payable in common stock at a future date tied to service on the board.
Elevance Health director Ryan M. Schneider received an equity grant of 563 deferred stock units of common stock as board compensation. The units were awarded at no cash cost and increase his directly held equity to 7,163 shares. These deferred stock units are scheduled to be settled in Elevance Health common stock on the earlier of five years from the grant date or when he leaves the board, unless he has elected a later distribution date under the company’s Board of Directors Deferred Compensation Plan. This is a routine, compensation-related acquisition rather than an open-market purchase.
PERU RAMIRO G reported acquisition or exercise transactions in this Form 4 filing.
Elevance Health director Ramiro G. Peru received an award of 563 deferred stock units of common stock on May 13. These units were granted at no cash cost as board compensation, increasing his direct holdings to 9,908 shares. The units will be settled in common stock after five years from grant or when he leaves the board, unless he has elected a later payout date.
Neri Antonio F reported acquisition or exercise transactions in this Form 4 filing.
Elevance Health, Inc. director Antonio F. Neri reported receiving a grant of 563 deferred stock units of common stock on May 13, 2026. These units were awarded at no cash cost under the company’s Board of Directors Compensation Program, increasing his direct holdings to 5,488 shares.
The deferred stock units will be settled in Elevance Health common stock upon the earlier of five years from the grant date or when he leaves the board, unless he has elected a later payout date under the Board of Directors Deferred Compensation Plan. This is a routine, compensation-related equity award rather than an open-market purchase.
Elevance Health, Inc. director Bahija Jallal reported an equity compensation grant in the form of deferred stock units tied to the company’s common stock. On the reported date, she acquired 563 shares-equivalent at a stated price of $0.00 per share as a grant or award, not an open-market purchase.
Following this award, Jallal’s direct holdings increased to 5,351 shares of Elevance Health common stock. The footnotes explain that these deferred stock units were accrued under the company’s Board of Directors Compensation Program and will be settled in common stock after a deferral period or when she leaves the board, subject to her prior deferral election.
HAY LEWIS III reported acquisition or exercise transactions in this Form 4 filing.
Elevance Health director Hay Lewis III reported a grant of 563 shares of common stock in the form of deferred stock units. These units were awarded at a price of $0.00 per share as part of the company’s Board of Directors Compensation Program.
Following this award, Lewis directly holds 12,070 shares of Elevance Health common stock. The deferred stock units will be settled in company stock after five years from grant or when he leaves the board, unless he has elected a later payout date under the board’s deferred compensation plan.
Dixon Robert L JR reported acquisition or exercise transactions in this Form 4 filing.
Elevance Health, Inc. director Robert L. Dixon Jr. received a grant of 563 shares of common stock in the form of deferred stock units under the company’s Board of Directors Compensation Program. Following this award, he directly holds 10,885 shares of Elevance Health common stock.
The deferred stock units will be settled in common stock upon the earlier of five years from the grant date or when Dixon ceases to serve on the board, unless he has elected a later payout date under the company’s Board of Directors Deferred Compensation Plan. This is a compensation-related award rather than an open-market purchase.
DeVore Susan D. reported acquisition or exercise transactions in this Form 4 filing.
Elevance Health director Susan D. DeVore received an award of 563 deferred stock units of common stock on May 13. The grant was made at no cash cost as part of the company’s Board of Directors Compensation Program and increases her direct holdings to 4,065 shares-equivalent.
The deferred stock units will be settled in Elevance Health common stock upon the earlier of five years from the grant date or when she leaves the board, unless she has elected a later payment date under the Board of Directors Deferred Compensation Plan.
COLLIS STEVEN H reported acquisition or exercise transactions in this Form 4 filing.
Elevance Health director Steven H. Collis reported an award of 563 deferred stock units of common stock. The units were granted at no cash price as part of the company’s Board of Directors Compensation Program, increasing his directly held equity units to 4,202.
The deferred stock units will be settled in Elevance Health common stock upon the earlier of five years from the grant date or when Collis leaves the board, unless he has elected a later date under the Board of Directors Deferred Compensation Plan.
Elevance Health, Inc. director Amy W. Schulman reported an open-market sale of common stock. On March 12, 2026, she sold 26 shares of Elevance Health common stock at a price of $287.50 per share. After this transaction, she directly owns 218 shares of Elevance Health common stock.
Elevance Health, Inc. executive Kendrick Charles Morgan Jr., EVP & President, Commercial, reported an open-market sale of common stock. On March 6, 2026, he sold 3,196 shares at a weighted average price of $284.92 per share, and held 11,791 shares afterward.
Elevance Health director Steven H. Collis reported an open-market purchase of common stock. On March 5, 2026, he bought 3,000 shares of Elevance Health at an average price of $289.84 per share. Following this transaction, he directly owns 3,639 common shares of the company.
Elevance Health chief accounting officer and controller Ronald W. Penczek reported several equity award changes. On March 2, 2026, he acquired common stock through grants and restricted share units, plus an employee stock option for 1,677 shares that vests in three annual installments starting on March 2, 2027. On March 2 and March 3, 2026, he disposed of small amounts of common stock through tax-withholding transactions tied to the vesting of previously granted restricted stock, rather than open-market sales. Footnotes show additional restricted share units with restrictions lapsing between 2027 and 2029, and participation in a dividend reinvestment plan in 2025.
Elevance Health EVP & Chief Legal Officer Erin M. Wessling reported equity compensation changes. On March 2, 2026, she received 2,976 shares of common stock as restricted share units and an option for 11,754 shares, vesting in three annual installments starting March 2, 2027. On March 3, 2026, 417 shares of common stock were disposed of at $284.03 per share to cover tax withholding upon vesting of previously granted restricted stock, leaving her with 7,579 common shares held directly.
Elevance Health EVP & Chief HR Officer Craig Ryan R reported multiple equity transactions. On March 2, 2026, he received an award of 11,754 employee stock options at an exercise price of $0.0000 per share, exercisable in three annual installments of 3,918 options beginning on March 2, 2027. He also acquired 2,976 shares of common stock as a grant, described as restricted share units with restrictions lapsing in three installments of 992 shares on March 2, 2027, March 2, 2028, and March 2, 2029. On March 2 and 3, 2026, a total of 334 common shares were disposed of at prices of $294.07 and $284.03 per share, respectively, as tax-withholding dispositions to cover liabilities upon vesting of previously granted restricted stock, rather than open‑market sales.
Elevance Health, Inc. executive Felicia F. Norwood reported equity compensation activity and related tax-withholding transactions. She received grants of 5,951 common shares and 2,865 performance-based restricted share units, plus an employee stock option covering 23,512 shares with future vesting installments.
To satisfy tax liabilities upon vesting of previously granted restricted stock, 496 common shares at $284.03 per share and 1,421 common shares at $294.07 per share were disposed of through stock withholding rather than open-market sales. Following these transactions, she directly owned 38,838 common shares.
Elevance Health EVP & Chief Digital Information Officer Ratnakar Lavu reported multiple equity compensation transactions. He received a grant of employee stock options covering 20,152 shares at an exercise price of $0.00 per share, exercisable in three installments beginning on 3/2/2027. He also acquired 5,101 and 6,802 shares that the footnotes describe as restricted share units with restrictions lapsing between 3/2/2027 and 3/2/2029. In separate transactions, 222 shares at $284.03 per share and 315 shares at $294.07 per share were withheld as common stock to satisfy tax liabilities on previously granted restricted stock vesting, rather than open-market sales.
Elevance Health EVP & President, Commercial, Kendrick Charles Morgan Jr. reported routine equity compensation changes. On March 2, 2026, he received 15,870 employee stock options exercisable in three equal annual installments starting on March 2, 2027, plus 6,549 common shares through restricted and performance-based stock unit awards. On March 2 and 3, 2026, a total of 1,678 common shares were disposed of at prices around $294.07 and $284.03, respectively, solely to cover tax liabilities upon vesting, leaving direct ownership of common stock.
Elevance Health EVP Peter D. Haytaian reported equity compensation activity in company common stock. On March 3, 2026, 446 shares were withheld at $284.03 per share, and on March 2, 2026, 1,201 shares were withheld at $294.07 per share to cover tax liabilities upon vesting of previously granted restricted stock. Also on March 2, he received a grant of 2,865 performance-based restricted share units as an award, bringing his directly held stake to 27,668 shares after these transactions.
Elevance Health EVP & CFO Mark Kaye reported multiple equity compensation transactions. He received grants of 6,377 and 10,202 restricted stock units, with restrictions scheduled to lapse between March 2, 2027 and March 2, 2029, and a stock option covering 25,188 shares exercisable in three annual installments beginning on March 2, 2027.
To cover tax liabilities tied to previously granted restricted stock vesting, he disposed of 353 and 271 common shares at prices of $284.03 and $294.07 per share through share withholding, rather than open-market sales.
Elevance Health President and CEO Gail Boudreaux reported a mix of equity grants and tax-related share dispositions. She received a grant of 63,818 employee stock options exercisable in three annual installments beginning on 3/2/2027. She was also awarded 16,153 and 10,527 common shares as restricted share unit and performance-based restricted share unit grants. To cover tax liabilities upon vesting of previously granted restricted stock, 1,736 common shares at $284.03 per share and 6,713 shares at $294.07 per share were withheld. After these transactions, she held 169,251 common shares directly, and 60 additional shares were reported as held indirectly in her spouse's revocable trust.
Elevance Health, Inc. director Amy W. Schulman reported an acquisition of 218 shares of Company common stock on February 2, 2026. The Form 4 shows these as an "A" transaction at a price of $0 per share, held as direct ownership after the transaction.
The 218 shares reflect phantom stock units accrued under Elevance Health’s Board of Directors Compensation Program. According to the terms, these phantom stock units will be settled in Company common stock on the earlier of five years after the preceding annual shareholder meeting or when Schulman ceases to serve on the board, unless she has elected a later deferral date.
Elevance Health EVP & Chief HR Officer Craig Ryan reported a routine tax-related share withholding. On February 2, 2026, 279 shares of Elevance Health common stock were withheld at $341.83 per share to cover tax liability from vesting restricted stock. After this transaction, he directly beneficially owned 4,032 common shares.
Mark Kaye, EVP & CFO of Elevance Health, Inc. (ELV), reported a sale of 2,895 shares of common stock on 10/02/2025 at a price of $340.24 per share. The filing states this disposition was a payment of tax liability by withholding stock related to the vesting of previously granted restricted stock. After the transaction, the reporting person beneficially owned 16,082 shares directly. The Form 4 was signed by an attorney-in-fact on 10/03/2025.